The CIA model would be well suited in order to verify the efficacy of CXCR5 targeting, being dependent both on T cells and B cells, mainly driven by anti-CII autoantibodies and due to its widespread use to develop current RA therapeutics such as TNFα inhibitors in pre-clinical trials57. Here, CXCR5 is linked to rheumatoid arthritis.